Literature DB >> 8794019

Macaque models for AIDS vaccine development.

R P Johnson1.   

Abstract

Recent vaccine trials utilizing the simian immunodeficiency virus/macaque model of AIDS are beginning to yield clues regarding mechanisms of protective immunity. Although cytotoxic T lymphocyte responses to SIV may play a role in mediating protection against infection, protective immunity appears to correlate best with the development of antibodies able to neutralize primary or heterologous pathogenic viruses. Protection against disease or persistent infection may be achieved in the absence of sterilizing immunity, suggesting that new benchmarks for AIDS vaccines may be in order.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8794019     DOI： 10.1016/s0952-7915(96)80046-x

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  9 in total

1.  Naturally occurring V1-env region variants mediate simian immunodeficiency virus SIVmac escape from high-titer neutralizing antibodies induced by a protective subunit vaccine.

Authors:  H Petry; K Pekrun; G Hunsmann; E Jurkiewicz; W Lüke
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Diverse peptide presentation of rhesus macaque major histocompatibility complex class I Mamu-A 02 revealed by two peptide complex structures and insights into immune escape of simian immunodeficiency virus.

Authors:  Jun Liu; Lianpan Dai; Jianxun Qi; Feng Gao; Youjun Feng; Wenjun Liu; Jinghua Yan; George F Gao
Journal:  J Virol       Date:  2011-05-11       Impact factor: 5.103

3.  Expression, purification, crystallization and preliminary X-ray diffraction analysis of rhesus macaque CD8alphaalpha homodimer.

Authors:  Lili Zong; Yong Chen; Jinghua Yan; Jianhua Zhang
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-03-31

4.  CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing.

Authors:  T M Allen; B R Mothé; J Sidney; P Jing; J L Dzuris; M E Liebl; T U Vogel; D H O'Connor; X Wang; M C Wussow; J A Thomson; J D Altman; D I Watkins; A Sette
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  Simian immunodeficiency virus promoter exchange results in a highly attenuated strain that protects against uncloned challenge virus.

Authors:  Philippe Blancou; Nicole Chenciner; Raphaël Ho Tsong Fang; Valérie Monceaux; Marie-Christine Cumont; Denise Guétard; Bruno Hurtrel; Simon Wain-Hobson
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

6.  Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.

Authors:  Helen Horton; Thorsten U Vogel; Donald K Carter; Kathy Vielhuber; Deborah H Fuller; Tim Shipley; James T Fuller; Kevin J Kunstman; Gerd Sutter; David C Montefiori; Volker Erfle; Ronald C Desrosiers; Nancy Wilson; Louis J Picker; Steven M Wolinsky; Chenxi Wang; David B Allison; David I Watkins
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

7.  Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication.

Authors:  Bianca R Mothé; Jason Weinfurter; Chenxi Wang; William Rehrauer; Nancy Wilson; Todd M Allen; David B Allison; David I Watkins
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

8.  Crystallization and preliminary X-ray crystallographic analysis of the rhesus macaque MHC class I molecule Mamu-B*17 complexed with an immunodominant SIVmac239 Env epitope.

Authors:  Feng Gao; Jinku Bao
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-05-24

Review 9.  FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review.

Authors:  E W Uhl; T G Heaton-Jones; R Pu; J K Yamamoto
Journal:  Vet Immunol Immunopathol       Date:  2002-12       Impact factor: 2.046
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.